BC-23

BC-23 (NSC 45382) is a proteasome inhibitor. BC-23 exhibits good inhibition of CT-L activity of the proteasome and is selective for malignant over normal cells[1][2].

Product Specifications

CAS Number

[6298-15-3]

Product Name Alternative

NSC 45382

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Proteasome

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bc-23.html

Purity

97.37

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(C1=CC=C(C=C1)NC(C2=O)=C(C(C3=C2C=CC=C3)=O)Cl)(NC4=NC=CC=C4)=O

Molecular Formula

C21H14ClN3O4S

Molecular Weight

439.87

Precautions

H302, H315, H319, H335

References & Citations

[1]Lawrence HR, et, al. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorg Med Chem. 2010 Aug 1;18 (15) :5576-92.|[2]Zhang Q, et, al. Enhancement of Radiation Sensitivity in Lung Cancer Cells by a Novel Small Molecule Inhibitor That Targets the β-Catenin/Tcf4 Interaction. PLoS One. 2016 Mar 25;11 (3) :e0152407.